title: Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.
abstract: Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day cycle. All patients were evaluated for toxicity and response. Overall, 83 cycles were administered, with a median number of 4 cycles per patient. Hematologic toxicity, not requiring hospitalization, was the major side effect. Vomiting occurred in 19.2% of cycles. Objective response rate was 33.3% (95% confidence interval: 12.2-53.1%); best responses were 1 complete and 6 partial; also 7 stable and 7 progressive disease were recorded. The best responding site was the viscera, the worst was bone. Responses were seen preferentially in second- rather than in third-line therapy and in patients who had responded to previous chemotherapy, although differences were not statistically significant. Kaplan-Meier estimated median time to progression and overall survival were 26 weeks (range: 2-67 weeks) and 35 weeks (range: 6-79 weeks), respectively. In conclusion the MM regimen showed acceptable toxicity and appreciable activity in anthracycline-pretreated advanced breast cancer.
authors.affiliation: Division of Medical Oncology, Medical School, University of Naples, Federico II, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Perrone
authors.forename: S
authors.initials: S
authors.lastname: De Placido
authors.forename: C
authors.initials: C
authors.lastname: Carlomagno
authors.forename: A
authors.initials: A
authors.lastname: Gravina
authors.forename: M
authors.initials: M
authors.lastname: De Laurentiis
authors.forename: L
authors.initials: L
authors.lastname: Del Mastro
authors.forename: C
authors.initials: C
authors.lastname: Gridelli
authors.forename: C
authors.initials: C
authors.lastname: Pagliarulo
authors.forename: A R
authors.initials: AR
authors.lastname: Bianco
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009362:Neoplasm Metastasis; D012074:Remission Induction; D016879:Salvage Therapy; D016019:Survival Analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D016685:Mitomycin; D008942:Mitoxantrone